Patents by Inventor Verena Staedtke

Verena Staedtke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12109177
    Abstract: Provided herein are methods for increasing the therapeutic efficiency of oncolytic bacterial therapeutics. Bacterial oncolytic therapies, especially the ones targeting tumor hypoxia such as C. novyi-NT, often encounter incomplete tumor clearance in less hypoxic tumoral areas and severe inflammatory reactions. In this study, we explored immune-modulating preconditioning to suppress the host neutrophils and significantly enhanced the antitumor efficacy of C. novyi-NT in animal models, including an orthotopic brain tumor model in rabbits. The optimized preconditioning agent, hydroxyurea, is clinically approved and C. novyi-NT has demonstrated manageable safety and promising antitumor responses in clinical trials. Thus, the proposed preconditioning of neutrophil suppression is readily translatable to patients undergoing C. novyi-NT trials or other oncolytic biologic therapies and could improve outcome.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 8, 2024
    Assignee: The Johns Hopkins University
    Inventors: Renyuan Bai, Verena Staedtke
  • Publication number: 20240115552
    Abstract: Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 11, 2024
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson
  • Patent number: 11850235
    Abstract: The invention provides methods of delaying or preventing NF1-related malignancies or tumors using mebendazole. The administration of mebendazole results in decreased Ras activation in NF1-related tumor cells. Invention methods include the use of a cyclooxygenase-2 inhibitor such as celecoxib in combination with mebendazole. The methods include methods of treatment and methods of prevention or delaying of neurofibromatosis type 1-related malignancies or tumors.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: December 26, 2023
    Assignee: The Johns Hopkins University
    Inventors: Verena Staedtke, Renyuan Bai
  • Publication number: 20230310549
    Abstract: This document relates to methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 5, 2023
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Verena Staedtke, Renyuan Bai, Gregory J. Riggins
  • Publication number: 20230201137
    Abstract: Provided herein are methods for increasing the therapeutic efficiency of oncolytic bacterial therapeutics. Bacterial oncolytic therapies, especially the ones targeting tumor hypoxia such as C. novyi-NT, often encounter incomplete tumor clearance in less hypoxic tumoral areas and severe inflammatory reactions. In this study, we explored immune-modulating preconditioning to suppress the host neutrophils and significantly enhanced the antitumor efficacy of C. novyi-NT in animal models, including an orthotopic brain tumor model in rabbits. The optimized preconditioning agent, hydroxyurea, is clinically approved and C. novyi-NT has demonstrated manageable safety and promising antitumor responses in clinical trials. Thus, the proposed preconditioning of neutrophil suppression is readily translatable to patients undergoing C. novyi-NT trials or other oncolytic biologic therapies and could improve outcome.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 29, 2023
    Inventors: Renyuan Bai, Verena Staedtke
  • Patent number: 11628204
    Abstract: This document provides methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 18, 2023
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Verena Staedtke, Renyuan Bai, Gregory J. Riggins
  • Publication number: 20230035885
    Abstract: The invention provides methods of delaying or preventing NF1-related malignancies or tumors using mebendazole. The administration of mebendazole results in decreased Ras activation in NF1-related tumor cells. Invention methods include the use of a cyclooxygenase-2 inhibitor such as celecoxib in combination with mebendazole. The methods include methods of treatment and methods of prevention or delaying of neurofibromatosis type 1-related malignancies or tumors.
    Type: Application
    Filed: July 7, 2021
    Publication date: February 2, 2023
    Inventors: Verena Staedtke, Renyuan Bai
  • Publication number: 20210395736
    Abstract: Provided herein is technology relating to treatment of Ras-associated diseases and particularly, but not exclusively, to compositions, methods, systems, and kits for decreasing Ras activity using a neurofibromin 1 GTPase-activating protein-related domain gene therapy construct.
    Type: Application
    Filed: October 29, 2019
    Publication date: December 23, 2021
    Inventors: Renyuan Bai, Verena Staedtke
  • Publication number: 20210369679
    Abstract: Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 2, 2021
    Applicant: The Johns Hopkins University
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson
  • Patent number: 11110079
    Abstract: Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: September 7, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson
  • Publication number: 20200368324
    Abstract: This document relates to methods and materials for preventing cytokine release syndrome (CRS). For example, methods and materials for using one or more catecholamine inhibitors to prevent a mammal from developing CRS are provided.
    Type: Application
    Filed: December 11, 2018
    Publication date: November 26, 2020
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Shibin Zhou, Verena Staedtke, Renyuan Bai, Gregory J. Riggins
  • Publication number: 20190231802
    Abstract: A chemotherapeutic-releasing implantable stick is described herein. The chemotherapeutic-releasing implantable stick includes an implantable stick having a length and thickness to fit within a needle track from a needle biopsy, the implantable stick providing a biocompatible and biodegradable substrate for the release of a chemotherapeutic agent when implanted. The chemotherapeutic-releasing implantable stick further includes a chemotherapeutic agent absorbed into the implantable stick.
    Type: Application
    Filed: October 18, 2017
    Publication date: August 1, 2019
    Applicant: The Johns Hopkins University
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke
  • Publication number: 20180021310
    Abstract: Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
    Type: Application
    Filed: February 8, 2016
    Publication date: January 25, 2018
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson